Logo image of VVY.AS

VIVORYON THERAPEUTICS NV (VVY.AS) Stock Fundamental Analysis

AMS:VVY - Euronext Amsterdam - NL00150002Q7 - Common Stock - Currency: EUR

1.784  -0.01 (-0.78%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VVY. VVY was compared to 71 industry peers in the Biotechnology industry. VVY has a great financial health rating, but its profitability evaluates not so good. VVY has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VVY has reported negative net income.
In the past year VVY has reported a negative cash flow from operations.
VVY had negative earnings in each of the past 5 years.
VVY had a negative operating cash flow in each of the past 5 years.
VVY.AS Yearly Net Income VS EBIT VS OCF VS FCFVVY.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of VVY (-166.81%) is worse than 78.87% of its industry peers.
Looking at the Return On Equity, with a value of -202.73%, VVY is doing worse than 63.38% of the companies in the same industry.
Industry RankSector Rank
ROA -166.81%
ROE -202.73%
ROIC N/A
ROA(3y)-77.76%
ROA(5y)-61.17%
ROE(3y)-96.83%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
VVY.AS Yearly ROA, ROE, ROICVVY.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

VVY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VVY.AS Yearly Profit, Operating, Gross MarginsVVY.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 400 600

More info and screens

7

2. Health

2.1 Basic Checks

VVY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VVY has been increased compared to 1 year ago.
Compared to 5 years ago, VVY has more shares outstanding
Compared to 1 year ago, VVY has an improved debt to assets ratio.
VVY.AS Yearly Shares OutstandingVVY.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
VVY.AS Yearly Total Debt VS Total AssetsVVY.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

VVY has an Altman-Z score of -8.84. This is a bad value and indicates that VVY is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of VVY (-8.84) is worse than 70.42% of its industry peers.
VVY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.84
ROIC/WACCN/A
WACC7.38%
VVY.AS Yearly LT Debt VS Equity VS FCFVVY.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 9.37 indicates that VVY has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.37, VVY belongs to the top of the industry, outperforming 94.37% of the companies in the same industry.
VVY has a Quick Ratio of 9.37. This indicates that VVY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.37, VVY belongs to the top of the industry, outperforming 94.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.37
Quick Ratio 9.37
VVY.AS Yearly Current Assets VS Current LiabilitesVVY.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for VVY have decreased by -7.14% in the last year.
EPS 1Y (TTM)-7.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VVY will show a small growth in Earnings Per Share. The EPS will grow by 0.92% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.13%
EPS Next 2Y16.99%
EPS Next 3Y9.38%
EPS Next 5Y0.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VVY.AS Yearly Revenue VS EstimatesVVY.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2023 2029 2030 0 500M 1B 1.5B
VVY.AS Yearly EPS VS EstimatesVVY.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 20 30 40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VVY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VVY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VVY.AS Price Earnings VS Forward Price EarningsVVY.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VVY.AS Per share dataVVY.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.99%
EPS Next 3Y9.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VVY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVORYON THERAPEUTICS NV

AMS:VVY (4/29/2025, 7:00:00 PM)

1.784

-0.01 (-0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-22 2025-04-22/amc
Earnings (Next)05-21 2025-05-21
Inst Owners14.38%
Inst Owner ChangeN/A
Ins Owners10.2%
Ins Owner ChangeN/A
Market Cap46.51M
Analysts77.5
Price Target5.36 (200.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-67.06%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)5.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.33
P/tB 3.56
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS-0.14
BVpS0.54
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -166.81%
ROE -202.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-77.76%
ROA(5y)-61.17%
ROE(3y)-96.83%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover-0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.37
Quick Ratio 9.37
Altman-Z -8.84
F-Score2
WACC7.38%
ROIC/WACCN/A
Cap/Depr(3y)110.94%
Cap/Depr(5y)86.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y16.13%
EPS Next 2Y16.99%
EPS Next 3Y9.38%
EPS Next 5Y0.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.41%
EBIT Next 3Y8.12%
EBIT Next 5Y6.22%
FCF growth 1Y-0.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.65%
OCF growth 3YN/A
OCF growth 5YN/A